Merck received FDA approval for its RSV antibody drug, Enflonsia, targeting infants under 12 months and directly competing with Sanofi and AstraZeneca’s Beyfortus. The approval occurs amid a sweeping reconstitution of the CDC’s Advisory Committee on Immunization Practices, whose entire membership was dismissed by HHS Secretary Robert F. Kennedy Jr. This unprecedented committee overhaul raises concerns about vaccine policymaking stability during critical immunization periods for vulnerable pediatric populations.